Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Abstract Background Basket clinical trials targeting the KRASG12C-mutation in solid tumors have shown initial promise, including in orphan KRASG12C head and neck cancer (HNC). However, development of resistance to KRASG12C-mutant-specific inhibitors (KRASG12Ci) remains a major obstacle. Here, we inv...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben-Lulu, Baisali Bhattacharya, Angel Porgador, Dexin Kong, Johannes Brägelmann, J. Silvio Gutkind, Moshe Elkabets
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-11-01
coleção:	Journal of Experimental & Clinical Cancer Research
Assuntos:	KRASG12C mutation Adagrasib Sotorasib Drug resistance Cell-autonomous Tumor microenvironment
Acesso em linha:	https://doi.org/10.1186/s13046-024-03227-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!